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Letters to the Editora New York Times article describing
our work. Dr Anthony Atala has a
much better claim to this milestone
achievement.
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We thank Dr Macchiarini for com-
menting on our editorial published in
the Journal, and we acknowledge his
team’s motivation and efforts to
advance tracheal replacement.
In his response to our editorial, Paolo
Macchiarini refers to several publica-
tions, thus undoubtedly convincing
many readers of his views. However,
in not one of these articles have morta-
lity rates been published. Furthermore,
we cannot follow his suggestion to rely
on an unpublished article to obtain this
information. Nor indeed can we refer
to its content, although we have been
in a position to read it. However, the un-
fortunate results after some of the treat-
ments with ‘‘bioengineered’’ tracheas366 The Journal of Thoracic and Chave reached investigative journalists
of Science1 and other media.2,3
More important, the purpose of our
editorial was to inform the scientific
community that regeneration of a
viable trachea resulting from applying
bone marrow cells to a decellularized
or a synthetic scaffold in the absence
of any blood supply is based on hope
and belief and not on scientific evi-
dence. None of the publications that
Macchiarini cites in his response pro-
vide scientific evidence for his claims.
We therefore strongly warn against
further unethical human experimenta-
tion. The ongoing clinical trials will
show whether or not this warning was
justified.
Pierre Delaere, MD, PhDa
Dirk Van Raemdonck, MD, PhDb
UZ Leuven
aENT Head and Neck Surgery
bThoracic Surgery
Leuven, BelgiumReferences
1. Vogel G. Trachea transplants test the limits.
Science. 2013;340:266-8.
2. Girl dies after groundbreaking trachea transplant.
Available at: http://abcnews.go.com/Health/girl-
dies-groundbreaking-trachea-transplant/story?id¼
19604605. Accessed July 8, 2013.
3. Recipient of synthetic trachea dies. Available at:
http://articles.baltimoresun.com/2012-03-06/health/
bs-hs-trachea-death-20120306_1_cell-research-wind
pipe-experimental-therapies. Accessed March 6,
2012.
http://dx.doi.org/10.1016/
j.jtcvs.2014.03.044MODIFIABLE RISK FACTORS
FOR ACUTE KIDNEY INJURY
AFTER CORONARYARTERY
BYPASS GRAFTING
To the Editor:
We read with interest the recent
article by Ng and colleagues1 that
identified modifiable risk factors
for acute kidney injury (AKI) after
coronary artery bypass grafting
(CABG) in an Asian population.
They showed that preoperative anemia
and intraoperative lowest hematocrit
were potentially modifiable risk fac-
tors independently associated withardiovascular Surgery c July 2014postoperative AKI. In the design of
this study, however, some important
data regarding patient perioperative
management, such as intraoperative
hemodynamic changes, fluid volume,
and use of vasoactive medicines,
were evidently missing. It has been
shown that intraoperative systolic
blood pressure decrease relative to
baseline is independently associated
with postoperative AKI in patients un-
dergoing CABG.2 Furthermore, the
combination of intraoperative hemodi-
lution anemia and hypotension can
synergistically act to increase the risk
of AKI after cardiac surgery.3 Camp-
bell and associates4 have demonstrated
that fluid volume before cardiopulmo-
nary bypass can contribute signifi-
cantly to intraoperative hemodilution
anemia and that restricting fluid vol-
ume before cardiopulmonary bypass
can attenuate intraoperative hemodilu-
tion anemia and decrease the need for
transfusion in patients undergoing
CABG. In addition, perioperative ino-
tropes, vasopressors, antiarrhythmics,
and diureticsmay also influence devel-
opment of AKI after cardiac surgery.
We therefore argue that optimizing
perioperative management, such as in-
traoperative avoidance of excess fluid
volume, hypotension, and renal arte-
rial vasoconstrictive drugs, should be
importantly modifiable factors in
decreasing the occurrence of postoper-
ative AKI in patients undergoing
CABG. We believe that the results of
this studywould have beenmore infor-
mative had these factors been taken
into account.
Ng and colleagues1 did not mention
the specific timing of postoperative
creatinine measurements. It was also
unclear whether continuous creatinine
measurements were performed. It is
therefore difficult to determine
whether the cases of AKI reported in
this study were due to intraoperative
or postoperative factors. Although
serum creatinine lags behind acute
changes in renal function, AKI
(defined by serum creatinine >10
mmol/L greater than normal values)
